TRPV4 and pulmonary edema: Moreover, pharmaceutical companies have considered TRPV4 a promising drug target to treat disease, e.g. bladder dysfunction [9], sepsis [10], and pulmonary edema [11,12], giving rise to novel selective small molecule modulators, such as the activator, GSK1016790A [13], and several selective inhibitors [1].